消化管ヒトマイクロバイオーム分野は、予測期間中に市場を牽引し、全体の需要の最大のシェアを占めると予想されます。この優位性は、炎症性腸疾患、過敏性腸症候群、クロストリジオイデス・ディフィシル感染症、代謝障害など、微生物バランスの乱れと密接に関連する消化器疾患の発生率が高いことに大きく支えられています。製薬企業は、この分野にますます注力し、臨床プログラムを拡大し、腸内フローラの回復を目的とした後期段階の候補薬の開発を加速させています。泌尿生殖器系やその他のマイクロバイオーム分野も着実に成長していますが、消化管は幅広い疾患との関連性と強力な臨床的検証に基づき、依然として主要な焦点領域となっています。
収益貢献度で見ると、病院薬局は現在、世界のヒトマイクロバイオーム医薬品市場を牽引しており、これは新規かつ高価なマイクロバイオーム治療薬の調剤における病院薬局の中心的な役割を反映している。多くのマイクロバイオーム医薬品は、特に商業化の初期段階において、管理された臨床環境で投与されるため、病院の流通ネットワークを通じてより多くの収益が自然と得られる。小売薬局やドラッグストアは、承認された治療法が慢性疾患治療の現場へと移行するにつれて徐々に追いつきつつあり、オンライン薬局は、デジタルヘルスの普及と患者直販モデルの拡大に後押しされ、最も急速に成長しているチャネルとして台頭している。この進化するチャネル構成は、臨床診療パターンと消費者の行動の両方によって積極的に再構築されている市場を浮き彫りにしている。
北アメリカは、強力な研究インフラ、多額のバイオ医薬品投資、そして主要なマイクロバイオームイノベーターの存在により、世界のヒトマイクロバイオーム医薬品市場において圧倒的な地位を占めています。この地域は、特にアメリカにおいて、早期の規制当局との連携と臨床試験の集中という恩恵を受けています。ヨーロッパは、堅固な学術研究、官民連携の取り組み、そして各国の医療制度におけるマイクロバイオームベースの治療法の受け入れ拡大に支えられ、これに続いています。アジア太平洋地域は、医療費の増加、バイオテクノロジーエコシステムの拡大、そして中国、日本、インドなどの国々におけるマイクロバイオーム科学への認識の高まりが需要を押し上げるため、予測期間を通じて最も急速に成長する地域になると予想されています。一方、ラテンアメリカと中東・アフリカは、高度な治療法へのアクセスが改善されるにつれて、徐々に新たな成長分野を開拓しています。
本調査の目的は、近年の様々なセグメントおよび各国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、定性的な洞察と定量的な分析を融合させ、調査対象地域全体におけるヒトマイクロバイオーム医薬品市場の包括的な概観を提供するように構成されています。成長促進要因、阻害要因、そして新たな機会に関する詳細な情報を提供するとともに、主要市場参加者の競争力と製品戦略についても分析しています。マイクロマーケットや将来を見据えた投資機会を掘り下げることで、本レポートは、急速に進化する医薬品分野をナビゲートするための実践的な視点を関係者に提供します。
目次
Table of Contents
Chapter 1. Global Human Microbiome Drugs Market Report Scope & Methodology
1.1. Research Objective
1.2. Research Methodology
1.2.1. Forecast Model
1.2.2. Desk Research
1.2.3. Top Down and Bottom-Up Approach
1.3. Research Attributes
1.4. Scope of the Study
1.4.1. Market Definition
1.4.2. Market Segmentation
1.5. Research Assumption
1.5.1. Inclusion & Exclusion
1.5.2. Limitations
1.5.3. Years Considered for the Study
Chapter 2. Executive Summary
2.1. CEO/CXO Standpoint
2.2. Strategic Insights
2.3. ESG Analysis
2.4. key Findings
Chapter 3. Global Human Microbiome Drugs Market Forces Analysis
3.1. Market Forces Shaping The Global Human Microbiome Drugs Market (2025-2035)
3.2. Drivers
3.2.1. rising prevalence of chronic gastrointestinal disorders
3.2.2. growing antibiotic resistance
3.3. Restraints
3.3.1. complex manufacturing processes and stringent regulatory scrutiny
3.4. Opportunities
3.4.1. Growing shift toward precision and personalized medicine
Chapter 4. Global Human Microbiome Drugs Industry Analysis
4.1. Porter’s 5 Forces Model
4.1.1. Bargaining Power of Buyer
4.1.2. Bargaining Power of Supplier
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Porter’s 5 Force Forecast Model (2025-2035)
4.3. PESTEL Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.3.5. Environmental
4.3.6. Legal
4.4. Top Investment Opportunities
4.5. Top Winning Strategies (2025)
4.6. Market Share Analysis (2025-2025)
4.7. Global Pricing Analysis And Trends 2025
4.8. Analyst Recommendation & Conclusion
Chapter 5. Global Human Microbiome Drugs Market Size & Forecasts by Type 2025-2035
5.1. Market Overview
5.2. Global Human Microbiome Drugs Market Performance - Potential Analysis (2025)
5.3. Gastrointestinal Tract Human Microbiome
5.3.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
5.3.2. Market size analysis, by region, 2025-2035
5.4. Urogenital Tract Human Microbiome
5.4.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
5.4.2. Market size analysis, by region, 2025-2035
5.5. Others
5.5.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
5.5.2. Market size analysis, by region, 2025-2035
Chapter 6. Global Human Microbiome Drugs Market Size & Forecasts by Application 2025-2035
6.1. Market Overview
6.2. Global Human Microbiome Drugs Market Performance - Potential Analysis (2025)
6.3. Hospital Pharmacies
6.3.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
6.3.2. Market size analysis, by region, 2025-2035
6.4. Retail Pharmacies
6.4.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
6.4.2. Market size analysis, by region, 2025-2035
6.5. Drug Stores
6.5.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
6.5.2. Market size analysis, by region, 2025-2035
6.6. Online Pharmacies
6.6.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
6.6.2. Market size analysis, by region, 2025-2035
Chapter 7. Global Human Microbiome Drugs Market Size & Forecasts by Product 2025-2035
7.1. Market Overview
7.2. Global Human Microbiome Drugs Market Performance - Potential Analysis (2025)
7.3. Human Microbiome Drugs
7.3.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
7.3.2. Market size analysis, by region, 2025-2035
7.4. Human Microbiome
7.4.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
7.4.2. Market size analysis, by region, 2025-2035
7.5. Supplements (Probiotics, Prebiotics, Synbiotics)
7.5.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
7.5.2. Market size analysis, by region, 2025-2035
7.6. Human Microbiome Diagnostics
7.6.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
7.6.2. Market size analysis, by region, 2025-2035
Chapter 8. Global Human Microbiome Drugs Market Size & Forecasts by Disease 2025-2035
8.1. Market Overview
8.2. Global Human Microbiome Drugs Market Performance - Potential Analysis (2025)
8.3. Infectious disease
8.3.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
8.3.2. Market size analysis, by region, 2025-2035
8.4. Gastrointestinal Disease
8.4.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
8.4.2. Market size analysis, by region, 2025-2035
8.5. Endocrine, and metabolic disorders
8.5.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
8.5.2. Market size analysis, by region, 2025-2035
8.6. Cancer
8.6.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
8.6.2. Market size analysis, by region, 2025-2035
8.7. Other Diseases
8.7.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
8.7.2. Market size analysis, by region, 2025-2035
Chapter 9. Global Human Microbiome Drugs Market Size & Forecasts by Drugs & Supplements Type 2025-2035
9.1. Market Overview
9.2. Global Human Microbiome Drugs Market Performance - Potential Analysis (2025)
9.3. Bacterial Consortia Transplantation (BCT)
9.3.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
9.3.2. Market size analysis, by region, 2025-2035
9.4. Fecal Microbiota Transplantation (FMT)
9.4.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
9.4.2. Market size analysis, by region, 2025-2035
9.5. Peptides
9.5.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
9.5.2. Market size analysis, by region, 2025-2035
9.6. Live Bacteria Products
9.6.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
9.6.2. Market size analysis, by region, 2025-2035
9.7. Others
9.7.1. Top Countries Breakdown Estimates & Forecasts, 2025-2035
9.7.2. Market size analysis, by region, 2025-2035
Chapter 10. Global Human Microbiome Drugs Market Size & Forecasts by Region 2025-2035
10.1. Growth Human Microbiome Drugs Market, Regional Market Snapshot
10.2. Top Leading & Emerging Countries
10.3. North America Human Microbiome Drugs Market
10.3.1. U.S. Human Microbiome Drugs Market
10.3.1.1. Type breakdown size & forecasts, 2025-2035
10.3.1.2. Application breakdown size & forecasts, 2025-2035
10.3.1.3. Product breakdown size & forecasts, 2025-2035
10.3.1.4. Disease breakdown size & forecasts, 2025-2035
10.3.1.5. Drugs & Supplements Type breakdown size & forecasts, 2025-2035
10.3.2. Canada Human Microbiome Drugs Market
10.3.2.1. Type breakdown size & forecasts, 2025-2035
10.3.2.2. Application breakdown size & forecasts, 2025-2035
10.3.2.3. Product breakdown size & forecasts, 2025-2035
10.3.2.4. Disease breakdown size & forecasts, 2025-2035
10.3.2.5. Drugs & Supplements Type breakdown size & forecasts, 2025-2035
10.4. Europe Human Microbiome Drugs Market
10.4.1. UK Human Microbiome Drugs Market
10.4.1.1. Type breakdown size & forecasts, 2025-2035
10.4.1.2. Application breakdown size & forecasts, 2025-2035
10.4.1.3. Product breakdown size & forecasts, 2025-2035
10.4.1.4. Disease breakdown size & forecasts, 2025-2035
10.4.1.5. Drugs & Supplements Type breakdown size & forecasts, 2025-2035
10.4.2. Germany Human Microbiome Drugs Market
10.4.2.1. Type breakdown size & forecasts, 2025-2035
10.4.2.2. Application breakdown size & forecasts, 2025-2035
10.4.2.3. Product breakdown size & forecasts, 2025-2035
10.4.2.4. Disease breakdown size & forecasts, 2025-2035
10.4.2.5. Drugs & Supplements Type breakdown size & forecasts, 2025-2035
10.4.3. France Human Microbiome Drugs Market
10.4.3.1. Type breakdown size & forecasts, 2025-2035
10.4.3.2. Application breakdown size & forecasts, 2025-2035
10.4.3.3. Product breakdown size & forecasts, 2025-2035
10.4.3.4. Disease breakdown size & forecasts, 2025-2035
10.4.3.5. Drugs & Supplements Type breakdown size & forecasts, 2025-2035
10.4.4. Spain Human Microbiome Drugs Market
10.4.4.1. Type breakdown size & forecasts, 2025-2035
10.4.4.2. Application breakdown size & forecasts, 2025-2035
10.4.4.3. Product breakdown size & forecasts, 2025-2035
10.4.4.4. Disease breakdown size & forecasts, 2025-2035
10.4.4.5. Drugs & Supplements Type breakdown size & forecasts, 2025-2035
10.4.5. Italy Human Microbiome Drugs Market
10.4.5.1. Type breakdown size & forecasts, 2025-2035
10.4.5.2. Application breakdown size & forecasts, 2025-2035
10.4.5.3. Product breakdown size & forecasts, 2025-2035
10.4.5.4. Disease breakdown size & forecasts, 2025-2035
10.4.5.5. Drugs & Supplements Type breakdown size & forecasts, 2025-2035
10.4.6. Rest of Europe Human Microbiome Drugs Market
10.4.6.1. Type breakdown size & forecasts, 2025-2035
10.4.6.2. Application breakdown size & forecasts, 2025-2035
10.4.6.3. Product breakdown size & forecasts, 2025-2035
10.4.6.4. Disease breakdown size & forecasts, 2025-2035
10.4.6.5. Drugs & Supplements Type breakdown size & forecasts, 2025-2035
10.5. Asia Pacific Human Microbiome Drugs Market
10.5.1. China Human Microbiome Drugs Market
10.5.1.1. Type breakdown size & forecasts, 2025-2035
10.5.1.2. Application breakdown size & forecasts, 2025-2035
10.5.1.3. Product breakdown size & forecasts, 2025-2035
10.5.1.4. Disease breakdown size & forecasts, 2025-2035
10.5.1.5. Drugs & Supplements Type breakdown size & forecasts, 2025-2035
10.5.2. India Human Microbiome Drugs Market
10.5.2.1. Type breakdown size & forecasts, 2025-2035
10.5.2.2. Application breakdown size & forecasts, 2025-2035
10.5.2.3. Product breakdown size & forecasts, 2025-2035
10.5.2.4. Disease breakdown size & forecasts, 2025-2035
10.5.2.5. Drugs & Supplements Type breakdown size & forecasts, 2025-2035
10.5.3. Japan Human Microbiome Drugs Market
10.5.3.1. Type breakdown size & forecasts, 2025-2035
10.5.3.2. Application breakdown size & forecasts, 2025-2035
10.5.3.3. Product breakdown size & forecasts, 2025-2035
10.5.3.4. Disease breakdown size & forecasts, 2025-2035
10.5.3.5. Drugs & Supplements Type breakdown size & forecasts, 2025-2035
10.5.4. Australia Human Microbiome Drugs Market
10.5.4.1. Type breakdown size & forecasts, 2025-2035
10.5.4.2. Application breakdown size & forecasts, 2025-2035
10.5.4.3. Product breakdown size & forecasts, 2025-2035
10.5.4.4. Disease breakdown size & forecasts, 2025-2035
10.5.4.5. Drugs & Supplements Type breakdown size & forecasts, 2025-2035
10.5.5. South Korea Human Microbiome Drugs Market
10.5.5.1. Type breakdown size & forecasts, 2025-2035
10.5.5.2. Application breakdown size & forecasts, 2025-2035
10.5.5.3. Product breakdown size & forecasts, 2025-2035
10.5.5.4. Disease breakdown size & forecasts, 2025-2035
10.5.5.5. Drugs & Supplements Type breakdown size & forecasts, 2025-2035
10.5.6. Rest of APAC Human Microbiome Drugs Market
10.5.6.1. Type breakdown size & forecasts, 2025-2035
10.5.6.2. Application breakdown size & forecasts, 2025-2035
10.5.6.3. Product breakdown size & forecasts, 2025-2035
10.5.6.4. Disease breakdown size & forecasts, 2025-2035
10.5.6.5. Drugs & Supplements Type breakdown size & forecasts, 2025-2035
10.6. Latin America Human Microbiome Drugs Market
10.6.1. Brazil Human Microbiome Drugs Market
10.6.1.1. Type breakdown size & forecasts, 2025-2035
10.6.1.2. Application breakdown size & forecasts, 2025-2035
10.6.1.3. Product breakdown size & forecasts, 2025-2035
10.6.1.4. Disease breakdown size & forecasts, 2025-2035
10.6.1.5. Drugs & Supplements Type breakdown size & forecasts, 2025-2035
10.6.2. Mexico Human Microbiome Drugs Market
10.6.2.1. Type breakdown size & forecasts, 2025-2035
10.6.2.2. Application breakdown size & forecasts, 2025-2035
10.6.2.3. Product breakdown size & forecasts, 2025-2035
10.6.2.4. Disease breakdown size & forecasts, 2025-2035
10.6.2.5. Drugs & Supplements Type breakdown size & forecasts, 2025-2035
10.7. Middle East and Africa Human Microbiome Drugs Market
10.7.1. UAE Human Microbiome Drugs Market
10.7.1.1. Type breakdown size & forecasts, 2025-2035
10.7.1.2. Application breakdown size & forecasts, 2025-2035
10.7.1.3. Product breakdown size & forecasts, 2025-2035
10.7.1.4. Disease breakdown size & forecasts, 2025-2035
10.7.1.5. Drugs & Supplements Type breakdown size & forecasts, 2025-2035
10.7.2. Saudi Arabia (KSA) Human Microbiome Drugs Market
10.7.2.1. Type breakdown size & forecasts, 2025-2035
10.7.2.2. Application breakdown size & forecasts, 2025-2035
10.7.2.3. Product breakdown size & forecasts, 2025-2035
10.7.2.4. Disease breakdown size & forecasts, 2025-2035
10.7.2.5. Drugs & Supplements Type breakdown size & forecasts, 2025-2035
10.7.3. South Africa Human Microbiome Drugs Market
10.7.3.1. Type breakdown size & forecasts, 2025-2035
10.7.3.2. Application breakdown size & forecasts, 2025-2035
10.7.3.3. Product breakdown size & forecasts, 2025-2035
10.7.3.4. Disease breakdown size & forecasts, 2025-2035
10.7.3.5. Drugs & Supplements Type breakdown size & forecasts, 2025-2035
Chapter 11. Competitive Intelligence
11.1. Top Market Strategies
11.2. Pfizer Inc.
11.2.1. Company Overview
11.2.2. Key Executives
11.2.3. Company Snapshot
11.2.4. Financial Performance (Subject to Data Availability)
11.2.5. Product/Services Port
11.2.6. Recent Development
11.2.7. Market Strategies
11.2.8. SWOT Analysis
11.3. Johnson & Johnson
11.4. Roche Holding AG
11.5. AbbVie Inc.
11.6. Novartis AG
11.7. GlaxoSmithKline plc
11.8. Sanofi S.A.
11.9. AstraZeneca plc
11.10. Merck & Co., Inc.
11.11. Takeda Pharmaceutical Company Limited
11.12. Eli Lilly and Company
11.13. Bristol Myers Squibb Company
11.14. Bayer AG
11.15. Biogen Inc.
11.16. Ferring Pharmaceuticals
List of Tables
Table 1. Global Human Microbiome Drugs Market, Report Scope
Table 2. Global Human Microbiome Drugs Market Estimates & Forecasts By Region 2025-2035
Table 3. Global Human Microbiome Drugs Market Estimates & Forecasts By Segment 2025-2035
Table 4. Global Human Microbiome Drugs Market Estimates & Forecasts By Segment 2025-2035
Table 5. Global Human Microbiome Drugs Market Estimates & Forecasts By Segment 2025-2035
Table 6. Global Human Microbiome Drugs Market Estimates & Forecasts By Segment 2025-2035
Table 7. Global Human Microbiome Drugs Market Estimates & Forecasts By Segment 2025-2035
Table 8. U.S. Human Microbiome Drugs Market Estimates & Forecasts, 2025-2035
Table 9. Canada Human Microbiome Drugs Market Estimates & Forecasts, 2025-2035
Table 10. UK Human Microbiome Drugs Market Estimates & Forecasts, 2025-2035
Table 11. Germany Human Microbiome Drugs Market Estimates & Forecasts, 2025-2035
Table 12. France Human Microbiome Drugs Market Estimates & Forecasts, 2025-2035
Table 13. Spain Human Microbiome Drugs Market Estimates & Forecasts, 2025-2035
Table 14. Italy Human Microbiome Drugs Market Estimates & Forecasts, 2025-2035
Table 15. Rest Of Europe Human Microbiome Drugs Market Estimates & Forecasts, 2025-2035
Table 16. China Human Microbiome Drugs Market Estimates & Forecasts, 2025-2035
Table 17. India Human Microbiome Drugs Market Estimates & Forecasts, 2025-2035
Table 18. Japan Human Microbiome Drugs Market Estimates & Forecasts, 2025-2035
Table 19. Australia Human Microbiome Drugs Market Estimates & Forecasts, 2025-2035
Table 20. South Korea Human Microbiome Drugs Market Estimates & Forecasts, 2025-2035
………….
List of Figures
Fig 1. Global Human Microbiome Drugs Market, Research Methodology
Fig 2. Global Human Microbiome Drugs Market, Market Estimation Techniques
Fig 3. Global Market Size Estimates & Forecast Methods
Fig 4. Global Human Microbiome Drugs Market, Key Trends 2025
Fig 5. Global Human Microbiome Drugs Market, Growth Prospects 2025-2035
Fig 6. Global Human Microbiome Drugs Market, Porter’s Five Forces Model
Fig 7. Global Human Microbiome Drugs Market, Pestel Analysis
Fig 8. Global Human Microbiome Drugs Market, Value Chain Analysis
Fig 9. Human Microbiome Drugs Market By Application, 2025 & 2035
Fig 10. Human Microbiome Drugs Market By Segment, 2025 & 2035
Fig 11. Human Microbiome Drugs Market By Segment, 2025 & 2035
Fig 12. Human Microbiome Drugs Market By Segment, 2025 & 2035
Fig 13. Human Microbiome Drugs Market By Segment, 2025 & 2035
Fig 14. North America Human Microbiome Drugs Market, 2025 & 2035
Fig 15. Europe Human Microbiome Drugs Market, 2025 & 2035
Fig 16. Asia Pacific Human Microbiome Drugs Market, 2025 & 2035
Fig 17. Latin America Human Microbiome Drugs Market, 2025 & 2035
Fig 18. Middle East & Africa Human Microbiome Drugs Market, 2025 & 2035
Fig 19. Global Human Microbiome Drugs Market, Company Market Share Analysis (2025)
………….
